Increased Levels of Vascular Endothelial Growth Factor and Advanced Glycation End Products in Aqueous Humor of Patients With Diabetic Retinopathy

Clinical studies have shown a relationship between diabetic retinopathy and vascular endothelial growth factor (VEGF) levels in ocular fluid. Advanced glycation end products (AGEs) have been implicated in diabetes complications, including diabetic retinopathy. N^ε-(carboxymethyl) lysine (CML) is a glycoxidation product that may be a marker of oxidative stress. In this study, we used enzyme-linked immunosorbent assays to determine the levels of VEGF, non-CML AGE and CML in the aqueous humor and serum of 82 Japanese patients with type 2 diabetes and 60 non-diabetic subjects. VEGF, non-CML AGE, and CML concentrations in aqueous humor and serum were then compared with the severity of diabetic retinopathy. Immunohistochemical detection analysis of non-CML AGE and CML was also performed using retinal tissues from patients with progressive diabetic retinopathy. Aqueous levels of VEGF, non-CML AGE and CML increased along with the progression of diabetic retinopathy compared to age-matched controls. After coagulation therapy, the VEGF, non-CML AGE, and CML levels were significantly reduced. Immunostaining showed diffuse co-localization of non-CML AGE and CML around microvessels and in the glial cells of proliferative membranes from patients with progressive diabetic retinopathy. These findings suggest that glycation and glycoxidation reactions (or oxidation, as revealed by CML) may contribute to both the onset and progression of diabetic retinopathy.

Key words:

AGE - Glycation - Glycoxidation - Vascular Endothelial Growth Factor - Diabetic Retinopathy - N^ε-(carboxymethyl) Lysine

References

• 1 Kuwabara T, Cogan D G. Retinal vascular patterns; Mural cells of the retinal capillaries.  Arch Ophthalmol. 1963;  69 492-502
• 2 Meyer-Schwickerath R, Pfeiffer A, Blum W F, Freyberger H, Klein M, Losche C, Rollmann R, Schatz H. Vitreous levels of the insulin growth factors I and II, and the insulin like growth factor binding protein 2 and 3, increase in neovascular eye disease; studies in nondiabetic and diabetic subjects.  J Clin Invest. 1993;  92 2620-2625
• 3 Sivalingham A, Kenney J, Brown G, Benson W, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy.  Arch Ophthalmol. 1990;  108 869-872
• 4 Tanaka Y, Katoh S, Hori S, Miura M, Yamashita H. Vascular endothelial growth factor in diabetic retinopathy.  Lancet. 1997;  349 1520
• 5 Aiello L P, Avery R L, Arrigg P G, Keyt B A, Jampel H D, Shah S T, Pasquale L R, Thieme H, Iwamoto M A, Park J E, Nguyen H V, Aiello L M, Ferrara N, King G L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med. 1994;  331 1480-1487
• 6 Pe’er J, Forberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy.  Br J Ophtalmol;. 1996;  80 241-245
• 7 Miller J W, Adamis A P, Shima D T, D’Amore P A, Moulton R S, Oreilly M S, Folkman J, Dvorak H F, Brown L F, Berse B, Yeo T K, Yeo K T. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.  Am J Pathol. 1994;  145 574-584
• 8 . The diabetes control and complications trial research group (DCCT) . The effect of intensive treatment of diabetes on the development and on progression of long-term complications in insulin-dependent diabetes mellitus.  N Eng J Med. 1993;  329 976-986
• 9 Brownlee M A, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications.  N Engl J Med.. 1988;  318 1315-1321
• 10 Makita Z, Bucala R, Rayfield E J, Friedman E A, Kaufman A M, Korbet S M, Barth R H, Winston J A, Fuh H, Monogue K R, Cerami A, Vlassara H. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure.  Lancet. 1994;  343 1519-1522
• 11 Makita Z, Radoff S, Rayfield E J, Yang Z, Skolnik E, Delaney V, Friedman E A, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy.  N Engl J Med.. 1991;  325 836-842
• 12 Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic retinopathy in rats by a novel advanced glycation end product inhibitor, OPB-9195.  Diabetologia. 1999;  42 579-588
• 13 Stitt A W, Li Y M, Gardiner T A, Bucala R, Archer D B, Vlassara H. Advanced glycation endproducts (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and AGE-infused rats.  Am J Pathol. 1997;  150 523-531
• 14 Fu M X, Requena J R, Jenkins A J, Lyons T J, Baynes J W, Thorpe S R. The advanced glycation end product, N^ε-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions.  J Biol. Chem1996;  271 9982-9986
• 15 Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.  Molecular Medicine. 1999;  5 393-405
• 16 Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor.  J Biol Chem. 1997;  272 8723-8730
• 17 Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation endproducts and expression of vascular endothelial growth factor in human diabetic retinas.  Diabetologia. 1997;  40 764-769
• 18 Hammes H P, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.  Proc Natl Acad Sci USA. 1991;  88 11 555-115 558
• 19 . Diabetes Control and Complications Trial Research Group . The effect of intensive diabetes treatment of the progression of diabetic retinopathy in insulin-dependent diabetes mellitus.  Arch Ophthalmolo. 1995;  113 36-51
• 20 Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.  Am J Pathol. 1998;  153 1149-1155
• 21 Stitt A W, Moore J E, Murphy G, Simpson D A, Bucala R, Vlassara H, Archer D B. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy.  Invest Opthalmol Vis Sci. 1998;  39 2517-2523
• 22 Lundquist O, Osterlin S. Glucose concentration in the vitreous of nondiabetic and diabetic human eyes.  Graefes Arch Clin Exp Opthalmol. 1994;  232 71-74
• 23 Reddy S, Bichker J, Welks-Knecht K J, Thorpe S R, Baynes J W. Nε-(Carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.  Biochemistry. 1995;  34 10 872-10 878
• 24 Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S. N^ε-(Carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction.  Biochemistry. 1996;  35 8075-8083
• 25 Schleicher E D, Wagner E, Nerlich A G. Increased accumulation of the glycoxidation product N^ε-(carboxymethyl) lysine in human tissues in diabetes and aging.  J Clin Invest. 1997;  99 457-468
• 26 Hood J D, Meininger C J, Ziche M, Granger H J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.  Am J Physiol. 1998;  274 H1054-H1058
• 27 Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, Strihou C, Kurokawa K. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis.  FEBS Letters. 1999;  463 260-264
• 28 Yamagishi S, Kobayashi K, Yamamoto H. Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells.  Biochemical Biophys Res Commun. 1993;  190 418-425
• 29 Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells.  Diabetologia. 1998;  41 1435-1441
• 30 Stitt A W, Moore J E, Sharkey J A, Murphy G, Simpson D AC, Bucala R, Vlassara H, Archer D B. Advanced Glycation End Products in vitreous: Structual and functional implications for diabetic vitreopathy.  Invest Opthalmol Vis Sci. 1998;  39 2517-2523